Market Overview

Vetr Upgrades Merrimack Following Earnings, Licensing Rumors

Share:
Related MACK
Benzinga's Option Alert Recap From February 3
Merrimack Pharma Is Taking Steps In The Right Direction

The Vetr crowd upgraded their rating for Merrimack Pharmaceuticals Inc (NASDAQ: MACK) from the previous rating of 2 stars (Sell), issued 20 days ago, to 5 stars (Strong Buy). Sentiment in the stock among the crowd is still middling, with 57 percent of Vetr user ratings bullish.

Interest in Merrimack jumped earlier this month upon rumors that the company was working with investment banks on the possibility of licensing its cancer treatment drug to larger biopharmaceutical companies. Shares of Merrimack traded recently around $6.03, about 10.7 percent lower from where it was at its post-rumor high of $6.75 on November 14.

See how crowdsourced ratings could help you time the markets.

The crowd's target price for Merrimack is at $10.86, which is just below the average analyst target price of $11.00. Less than 2 percent of Vetr users are holding MACK in their watch lists.

Latest Ratings for MACK

DateFirmActionFromTo
Oct 2016JP MorganDowngradesOverweightNeutral
Aug 2016BTIG ResearchInitiates Coverage onNeutral
Aug 2016JP MorganMaintainsOverweight

View More Analyst Ratings for MACK
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Rumors Crowdsourcing Analyst Ratings General

 

Related Articles (MACK)

View Comments and Join the Discussion!